Drug Profile

CP 102 - Contera Pharma

Alternative Names: CP-102 - Contera Pharma

Latest Information Update: 15 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

15 Oct 2024 Discontinued - Preclinical for Metachromatic leukodystrophy in Denmark (unspecified route), prior to October 2024 (Contera Pharma pipeline, October 2024)
15 Oct 2024 Preclinical trials in Canavan disease in Denmark (unspecified route), prior to October 2024 (Contera Pharma pipeline, October 2024)
28 Nov 2022 Preclinical trials in Metachromatic leukodystrophy in Denmark (unspecified route) (Contera Pharma pipeline, November 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com